A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)

Pre-Inclusion Criteria: * Male or female patients ≥ 18 and ≤ 75 years of age * Patients must have signed informed consent * A negative pregnancy test for women with childbearing potential * Patients with stage IIIc/IV metastatic melanoma (AJCC 6th edition) with nodal relapse, in transit metastasis, unresectable cutaneous metastases, visceral metastases except bone and brain metastases * Presence of at least one lesion accessible for intra-tumoral injections of Ad-IFNg * A negative brain scan, eliminating any brain metastases * ECOG performance status of 0-2 * Adequate bone-marrow reserve, renal function and hepatic function as assessed by standard laboratory criteria * Subjects affiliated to an appropriate social security system Inclusion Criteria: * Negative viral serology (HIV ½, p24 Ag, HTLV 1 / 2, B and C hepatitis) Exclusion Criteria: * For female : the patient is pregnant or lactating or not using contraception and proved by a negative pregnancy test * Positive viral serology for HIV ½, p24 Ag, HTLV 1 / 2 or B and C hepatitis * History or current manifestations of severe progressive heart disease (congestive heart failure, coronary artery disease, uncontrolled arterial hypertension, serious rhythm disorders or ECG signs of previous myocardial infarction) * Any serious illness, acute or chronic, e.g. active infection requiring antibiotics, bleeding disorders or any other condition that requires concomitant medications not allowed during this study * Presence of a second active cancer except in situ cervical cancer or skin carcinoma * Intercurrent disease requiring a corticosteroid treatment or a treatment with interferon-α * Any autoimmune disease including active diabetes mellitus or immunodeficiency. Vitiligo in not an exclusion criteria * Uncontrolled thyroid dysfunction * Concurrently participation in a biomedical research (drug or radiotherapy) within the month preceding inclusion * Metastatic lymph node stage alone with an indication of lymphadenectomy * Brain or bone metastases discovered by radiological examination during the inclusion assessment * Surgically resectable metastases * Ocular melanoma * More than one line of chemotherapy for treatment of melanoma * Chemotherapy, immunotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-ureas and mitomycin C) * Contraindication for the use of vasopressor agents * Treatment with molecules in pre-marketing development or whose development is finished less than 4 weeks